Takeda

This study tests a dengue vaccine in adults aged 45 to 79, including those with diabetes, high blood pressure, or kidney disease. Participants receive two shots three months apart. Researchers will check for side effects and measure the immune response. The goal is to see if the …

This study tests a drug called TAK-861 for people with narcolepsy type 1, a condition that causes sudden sleep attacks and muscle weakness. About 88 adults will take the drug for a few months, then some will switch to a placebo to see if symptoms return. The goal is to find out i…

This study looks at how well the drug teduglutide works for children aged 1 to 17 with short bowel syndrome who need IV nutrition to survive. The goal is to see if the drug can reduce the amount of IV nutrition they need, or even let them stop it completely. Researchers will revi…

This study looks at the long-term safety and effectiveness of the drug zasocitinib for adults with psoriatic arthritis, a condition that causes joint pain and skin problems. Participants who completed a one-year study on this drug can join and will take zasocitinib daily for up t…

This study looks at how often high blood pressure happens in Black/African American and Hispanic/Latino adults with advanced colorectal cancer who take the drug fruquintinib. About 78 participants will receive the drug in 4-week cycles until their cancer gets worse or side effect…

This study tests a drug called mezagitamab for adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. The goal is to see if monthly shots under the skin can keep platelet counts stable for 6 months compare…

This study looks at medical records of 50 people in Saudi Arabia with hereditary angioedema (HAE) who have been taking Takhzyro (lanadelumab) for at least 6 months to prevent swelling attacks. Researchers want to see how well the drug reduces disease activity and improves quality…

This study tests a new oral drug called zasocitinib (TAK-279) for active psoriatic arthritis, a condition causing joint pain and skin problems. About 1,088 adults who have not tried biologic treatments will receive either zasocitinib, an active comparator, or a placebo for up to …

This study in Japan looks at the drug Maribavir for treating CMV infection in organ or stem cell transplant patients when other treatments have failed. About 250 participants will take Maribavir as part of their regular care, and doctors will monitor side effects and how well the…

This study tests a new oral medication called zasocitinib for adults with nonsegmental vitiligo, a condition where the immune system attacks pigment cells, causing white patches on the skin. About 200 participants will receive either the drug or a placebo for up to a year to see …

This study is checking how safe and effective OBIZUR is for adults with acquired hemophilia A, a rare condition that causes sudden, severe bleeding. Researchers will track side effects and how well the drug controls bleeding in 9 participants in South Korea. The treatment is alre…

This study tracks side effects of the drug ADCETRIS when used with standard chemotherapy in children and teenagers with untreated Hodgkin lymphoma. About 8 participants in Japan will receive the treatment as part of their normal care. Doctors will watch for serious side effects l…

This program offers continued access to an experimental treatment called recombinant von Willebrand factor (rVWF) for people with severe von Willebrand disease who have already benefited from it in a prior study. It is for both children and adults who have no other suitable treat…

This study tests a medicine called vedolizumab in children with chronic pouchitis, an inflammation of an internal pouch created after bowel surgery. The goal is to see if the drug can reduce symptoms and heal the pouch lining. About 30 children will receive infusions over several…

This study tests a new drug called elritercept against a standard treatment (epoetin alfa) for anemia caused by a bone marrow disorder (myelodysplastic syndromes). About 300 adults who need regular blood transfusions will take part. The goal is to see if elritercept can reduce or…

This study follows 75 adults in Belgium who have had a stem cell or solid organ transplant and developed a CMV infection. Researchers will collect data from routine doctor visits over 2 years to see how effective and safe maribavir is in everyday practice. The goal is to understa…

This study looks at the long-term safety of the drug vedolizumab in children and teenagers with ulcerative colitis or Crohn's disease. About 70 participants who responded well to treatment in an earlier study will continue receiving the drug, while those who did not respond well …

This study follows 30 adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who are switching to the treatment HyQvia. Researchers will use questionnaires and medical records to understand why patients chose to switch, how satisfied they are, and how the treatment …

This study tests whether giving two drugs together (vedolizumab and upadacitinib) for 12 weeks works better than vedolizumab alone to reduce bowel inflammation and ulcers in adults with moderate to severe Crohn's disease. About 396 participants will receive the combo or a placebo…

This study tests a subcutaneous (under-the-skin) version of vedolizumab in children aged 2-17 with moderate to severe ulcerative colitis or Crohn's disease who already responded to IV vedolizumab. The goal is to see how the body handles the shot and check for side effects. About …

This study tests whether a new drug, TAK-881, works as well as an existing treatment (HYQVIA) for adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), a long-term nerve condition. About 59 participants who already receive immunoglobulin therapy will switc…

This study tests whether a monthly infusion of vonicog alfa (a lab-made clotting protein) can prevent bleeding episodes in 24 children with severe von Willebrand disease. Participants receive the treatment for 12 months and visit the clinic 5 times. The main goal is to see if the…

This study tests a new drug called elritercept (KER-050) in about 135 adults with myelofibrosis, a rare bone marrow disorder. The drug is given alone or with the standard medicine ruxolitinib. The main goals are to check safety and see if it helps with anemia and other symptoms. …

This study tracks side effects, especially lung problems, in 500 Japanese people with a specific type of non-small cell lung cancer taking Brigatinib. Doctors will monitor participants for 1 year as they receive standard treatment. The goal is to better understand the drug's safe…

This program provides continued access to vedolizumab, a medication given through a vein, for children and teenagers with moderate to severe ulcerative colitis or Crohn's disease. It is for those who completed a prior study and still benefit from the treatment, with no good alter…

This study follows 200 Chinese children and adults with Fabry disease, a rare inherited disorder that causes harmful fat buildup in blood vessels. Participants receive Replagal (agalsidase alfa) as part of their routine care. Researchers will track changes in heart and kidney fun…

This study looks at how well the drug brentuximab vedotin (BV) works to keep Hodgkin lymphoma from coming back after a stem cell transplant. About 70 adults will take BV as part of their normal care and be followed for up to 2 years. The goal is to see how long people stay cancer…

This study tests a new medicine called TAK-188 in adults with advanced solid tumors that have not improved with standard treatments. TAK-188 targets and removes certain cells inside tumors that weaken the immune system, potentially allowing the body's cancer-fighting cells to wor…

This study tests whether vedolizumab, a drug that reduces gut inflammation, can help children with moderate to severe Crohn's disease stay in remission. About 120 kids who respond to an initial 6-week treatment will receive either a high or low dose every 8 weeks for up to a year…

This study tests a drug called maribavir in Chinese adults who have had a stem cell or organ transplant and have a CMV infection that doesn't respond to standard treatments. The main goal is to check the drug's safety and how well patients tolerate it. Researchers will also see i…

This study tests whether giving immune globulin infusions regularly can prevent serious infections in adults with multiple myeloma who are receiving a type of immunotherapy called bispecific antibody therapy. About 183 participants will be randomly assigned to receive the infusio…

This study tests an experimental drug called elritercept in adults with a bone marrow disorder (MDS) who need regular red blood cell transfusions. The main goal is to see if the drug can help patients go without transfusions for at least 8 weeks. About 225 participants will recei…

This study monitors the safety and effectiveness of the drug LIVTENCITY (Maribavir) in adults who develop cytomegalovirus (CMV) infection after an organ or stem cell transplant. Researchers will collect data from 168 participants over about 5 months to see how well the drug works…

This study monitors side effects and how well brigatinib works in adults with a specific type of advanced lung cancer (ALK-positive NSCLC) in South Korea. About 257 people who are starting brigatinib for the first time will take part. The goal is to see how safe and effective the…

This study is for adults with moderate to severe Crohn's disease or ulcerative colitis who have already responded to the study drug zasocitinib (TAK-279) in a previous trial. The main goal is to check the long-term safety of this oral medication over up to 3 years. Researchers wi…

This study tests a drug called vedolizumab for adults in China with moderate to severe Crohn's disease, a condition that causes gut inflammation. About 408 participants will receive either the drug or a placebo through an IV, with the goal of reducing symptoms like abdominal pain…

This study monitors 25 people in Japan with Acquired Hemophilia A who receive OBIZER (Susoctocog Alfa) to control bleeding. Doctors will record side effects and how well the drug works for up to 90 days after the last dose. The goal is to gather real-world safety data, not to tes…

This study tests an oral medication called TAK-279 in 268 adults with moderate to severe Crohn's disease, a condition that causes long-term gut inflammation. Participants will receive one of three doses of TAK-279 or a placebo daily for a year. The main goal is to see if the drug…

This study tests a drug combination (brentuximab vedotin plus AVD) in 124 Indian adults with untreated stage 3 or 4 Hodgkin lymphoma. The goal is to see how safe and effective the treatment is over about 6 months. Participants will have heart and lung tests during the study and a…

This study in Japan looks at the safety and effectiveness of Vonvendi (rVWF) in children under 18 with von Willebrand disease. Doctors will monitor side effects and how well the drug controls bleeding during normal use over one year. About 13 kids will take part, and the drug is …

This study tests a medicine called fazirsiran for people with Alpha-1 antitrypsin deficiency who already have mild liver scarring. The drug works by reducing the buildup of an abnormal protein in the liver that causes damage. About 50 participants will receive either fazirsiran o…

This study tests whether taking two medications together—vedolizumab and tofacitinib—can help adults with moderate to severe ulcerative colitis achieve remission. Participants receive both drugs for 8 weeks, then those who respond continue with vedolizumab alone for nearly a year…

This study tests a new oral drug, zasocitinib, for adults with moderate to severe hidradenitis suppurativa (HS), a skin condition causing painful bumps and abscesses. About 90 participants will receive either the drug or a placebo for 4 months, then all will get the drug for 8 mo…

This study looks at the long-term safety of the drug vedolizumab in children with ulcerative colitis or Crohn's disease. It is for kids who already completed a previous study on this drug. Researchers will track side effects and major bowel-related events over time.

This study tests a drug called TAK-755 in adults who have had a stroke caused by a blood clot. The goal is to see if it is safe and helps reduce disability compared to a placebo. About 222 participants will receive either TAK-755 or a placebo once, along with standard stroke care…

This early-stage study tests whether the drug TAK-781 is safe and tolerable. It first gives single or multiple doses to healthy volunteers, then a single dose to people with non-cirrhotic primary sclerosing cholangitis (PSC). The study does not aim to cure PSC, but to gather safe…

This study looks at the long-term safety of the drug TAK-861 in 500 people with type 1 narcolepsy who have already taken it in earlier trials. Researchers will track side effects and measure how well participants can stay awake. The goal is to see if the drug remains safe and eff…

This study tests a medicine called zasocitinib in children and teens aged 4 to 17 with moderate-to-severe plaque psoriasis. The goal is to see if it clears or nearly clears the skin and is safe. Participants will take the drug or a placebo for 16 weeks, then everyone gets the rea…

This study tests a new medicine, TAK-505, for the first time in people with advanced solid tumors that cannot be removed by surgery. The main goals are to check safety, find the best dose, and see if it can shrink or slow tumor growth. About 151 adults with certain cancers like s…

This study tests whether using two drugs together (vedolizumab plus either adalimumab or ustekinumab) can better control moderate to severe Crohn's disease than one drug alone. About 100 adults will first receive the combination for 26 weeks, then those who respond will switch to…

This study tests a new daily pill, zasocitinib, for people with active psoriatic arthritis — a condition causing joint pain and skin patches. About 600 adults will receive either the drug or a placebo for up to 60 weeks. The goal is to see if the drug reduces joint swelling and t…

This study tracks side effects of the drug ADZYNMA in 40 people with congenital thrombotic thrombocytopenic purpura (cTTP), a rare blood clotting condition. Participants receive the drug as part of their normal care, and doctors monitor them for 18 months. The goal is to see how …

This study looks at whether a medicine called vedolizumab can help people with moderate to severe ulcerative colitis or Crohn's disease achieve remission (no symptoms) after 14 weeks. About 400 adults will receive vedolizumab for 1 year, starting with IV infusions and then switch…

This study follows 275 people in Japan who receive darvadstrocel injections for complex anal fistulas caused by Crohn's disease. Researchers will monitor side effects and check if the treatment helps close the fistulas over 36 months. The goal is to see if this cell therapy can i…

This study tests a drug called mezagitamab in people with IgA nephropathy, a kidney disease caused by protein buildup in the kidneys. About 347 adults will receive either the drug or a placebo for two years. The main goal is to see if the drug lowers protein in the urine, a sign …

This study tests an experimental drug called fazirsiran in people with Alpha-1 antitrypsin deficiency who have liver scarring (fibrosis). The goal is to see if fazirsiran can reduce scarring and slow liver disease compared to a placebo. About 160 adults aged 18 to 75 will partici…

This study tests a new drug called TAK-330 to reverse the effects of common blood thinners (Factor Xa inhibitors) in patients who need urgent surgery. About 328 adults will be randomly assigned to receive TAK-330 or standard care before their procedure. The main goal is to see if…

This study tests an experimental drug called elritercept (KER-050) in 160 adults with a type of bone marrow disorder (myelodysplastic syndromes) that causes low red blood cells and anemia. The main goals are to check the drug's safety and how well people tolerate different doses,…

This study tests a drug called VONVENDI (recombinant von Willebrand factor) to see if it is safe and effective at controlling bleeding in Chinese adults with von Willebrand disease, a rare bleeding disorder. About 20 participants will receive the drug, sometimes combined with ano…

This study tests the long-term safety of mezagitamab, a drug given as a shot under the skin, for adults with chronic immune thrombocytopenia (ITP). ITP is a condition where the immune system destroys platelets, raising the risk of bruising and bleeding. About 150 participants who…

This study tests a drug called maribavir for children and teens who have a CMV infection after a stem cell or organ transplant. About 80 participants will take the drug for 8 weeks and be followed for 12 more weeks. The goal is to find the best dose and check if it is safe and wo…

This program offers ongoing access to idursulfase-IT (TAK-609) for children and adults with Hunter syndrome who have cognitive impairment and completed earlier clinical trials. Participants receive the drug directly into the spine alongside their regular intravenous enzyme therap…

This study tests a new medicine called TAK-411 for people with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), a condition where the immune system attacks nerve coverings, causing weakness and numbness. The goal is to see if TAK-411 can improve physical function…

This study looks at how HyQvia, a treatment to boost the immune system, is used in real-world clinics for people with multiple myeloma who have a weakened immune system (secondary immunodeficiency). Researchers will track details like dose, infusion speed, and where the treatment…

This study looks at whether measuring just one protein function (C1-inhibitor) can accurately diagnose hereditary angioedema (HAE), a rare condition causing sudden swelling. About 514 people in Algeria who are suspected of having HAE or have family members with it will take part.…

This study tests if the drug vortioxetine can safely reduce depression symptoms in Japanese teenagers aged 12 to 17 with major depressive disorder. About 180 participants will receive either the drug or a placebo daily for 14 weeks, with follow-up for 4 more weeks. The goal is to…

This study tests a new drug called TAK-360 in 96 adults with idiopathic hypersomnia, a condition causing extreme daytime sleepiness despite long sleep. The drug mimics a brain chemical that promotes wakefulness. Researchers will check safety and whether TAK-360 helps people stay …

This study tests an experimental drug called TAK-360 in 88 adults with narcolepsy type 2 (NT2), a condition that causes severe daytime sleepiness. TAK-360 acts like a natural brain chemical that promotes wakefulness. The main goals are to check the drug's safety and see if it hel…

This study aims to find out how many people in Spain have been diagnosed with narcolepsy type 1 or type 2, and how many new cases appear each year. Researchers will review medical records from hospitals across Spain to count patients and understand patterns. The study does not te…

This study monitors side effects and survival in 600 adults with colorectal cancer who are prescribed fruquintinib in South Korea. It does not test a new treatment but collects real-world safety data. Participants must be 18 or older and starting the drug as approved.

This study looks at how much of the constipation medicine prucalopride gets into breast milk. About 12 breastfeeding women taking the drug will provide milk samples over 24 hours. Researchers will also track the growth and health of their babies for one year to check for any side…

This study looks at whether the dengue vaccine (TDV) reduces the chance of being hospitalized with dengue in children and teens. About 70,000 participants in Thailand, Indonesia, and Malaysia will be followed for 3 years. Researchers will compare hospital stays between those who …

This study looks at how often liver problems happen in Japanese children with Alagille syndrome or progressive familial intrahepatic cholestasis who take the drug Livmarli (maralixibat). Researchers will use a national liver disease registry to track side effects. The goal is to …

This study observes children aged 2 to 12 with hereditary angioedema (HAE) who are already taking lanadelumab to prevent swelling attacks. Researchers will review medical records to see how often attacks occur and how the treatment is used in real life. No new drugs or procedures…

This study looks at medical records of about 100 people in Japan with primary immunodeficiency (a weak immune system) who are taking Cuvitru. The goal is to see how often serious side effects like allergic reactions, blood clots, or meningitis happen. No new treatments are given—…

This study looks at 600 adults in South Korea who are already receiving vedolizumab injections for ulcerative colitis or Crohn's disease. Researchers will review medical records to track side effects and see how well the treatment works. No new treatments are given—this is just a…

This study uses a survey to see how well patients and doctors understand the risks and required checkups for the drug GATTEX, used to treat Short Bowel Syndrome. About 600 people—adults who have taken GATTEX in the last 60 days and their healthcare providers—will answer true/fals…

This study follows 500 adults with Alpha-1 antitrypsin deficiency (AATD) for up to 5 years to see how their liver disease naturally changes without treatment. Researchers will track liver scarring, symptoms, and lung health using medical records and yearly questionnaires. The goa…

This study looks at the safety of the drug maribavir in adults who have had an organ transplant and are fighting a virus called CMV, but also have severe kidney disease or kidney failure. Researchers will review medical records from about 10 patients to see what side effects occu…